About GLP Semaglutide

GLP Semaglutide covers the GLP-1 medication category — semaglutide, tirzepatide, and related drugs — through three lenses: product comparisons, industry news, and regulatory policy across the United States, European Union, and China.

We are an independent editorial publication. We do not sell medication, operate a pharmacy, or accept payment for product placement. Where we describe regulatory status, shortage designations, or approval timelines, we aim to cite primary sources (FDA, EMA, NMPA, and company disclosures) and to flag when something is fast-moving or subject to change.

Nothing on this site is medical advice. Decisions about whether a GLP-1 medication is appropriate for you, at what dose, and through what channel, should be made with a licensed healthcare provider who knows your medical history.

Have a correction? We’d want to know — regulatory and pipeline information changes quickly, and we’d rather fix an error than leave it standing.